Literature DB >> 22421303

Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation.

Hae-Geun Song1, Duk-Woo Park, Young-Hak Kim, Jung-Min Ahn, Won-Jang Kim, Jong-Young Lee, Soo-Jin Kang, Seung-Whan Lee, Cheol Whan Lee, Seong-Wook Park, Seungbong Han, In-Whan Seong, Nae-Hee Lee, Bong-Ki Lee, Keun Lee, Seung-Wook Lee, Deuk-Young Nah, Seung-Jung Park.   

Abstract

OBJECTIVES: The purpose of this study is to compare the efficacy of the treatment strategies for in-stent restenosis (ISR) of drug-eluting stents (DES) according to the morphologic pattern of restenosis.
BACKGROUND: Optimal treatment strategies for ISR within DES have not been adequately addressed yet.
METHODS: Patients with ISR of DES were randomized according to the lesion length to compare outcomes of sirolimus-eluting stent (SES) versus cutting balloon angioplasty for focal type (≤10 mm) and SES versus everolimus-eluting stent (EES) for diffuse type (>10 mm). The primary endpoint was in-segment late loss at 9 months. Overall 162 patients, 96 with focal ISR and 66 with diffuse ISR, were enrolled.
RESULTS: In focal lesions, in-segment late loss was significantly higher in the cutting balloon group (n = 48) than in the SES group (n = 48; 0.25 mm, interquartile range [IQR]: -0.01 to 0.68 mm vs. 0.06 mm, IQR: -0.08 to 0.17 mm; p = 0.04). Consequently, in-segment restenosis rate tended to be higher in the cutting balloon group than in the SES group (20.7% vs. 3.1%, p = 0.06) with comparable incidences of the composite of death, myocardial infarction, or target vessel revascularization at 12 months of clinical follow up (6.3% vs. 6.3%, p > 0.99). In 66 cases of diffuse ISR, in-segment late loss (0.11 mm, IQR: -0.02 to 0.30 mm; vs. 0.00 mm, IQR: -0.08 to 0.25 mm; p = 0.64), in-segment restenosis rate (5.0% vs. 14.3%, p = 0.32), and the composite incidence of death, myocardial infarction, or target lesion revascularization (9.6% vs. 8.8%, p > 0.99) did not differ between SES group (n = 32) and EES group (n = 34).
CONCLUSIONS: For lesions of focal DES restenosis, repeat implantation of SES is more effective in reducing late luminal loss and subsequent restenosis rate than cutting balloon angioplasty. For diffuse DES restenosis, implantation of SES or EES is comparably effective in terms of angiographic and clinical outcomes. Copyright Â
© 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22421303     DOI: 10.1016/j.jacc.2011.11.047

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

1.  In-stent restenosis: local drug delivery with a stent or balloon?

Authors:  Matias B Yudi; Ron Waksman; Andrew E Ajani
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

Review 2.  Highlights of the year in JACC 2012.

Authors:  Anthony N DeMaria; Jeroen J Bax; Gregory K Feld; Barry H Greenberg; Jennifer L Hall; Mark A Hlatky; Wilbur Y W Lew; João A C Lima; Ehtisham Mahmud; Alan S Maisel; Sanjiv M Narayan; Steven E Nissen; David J Sahn; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2013-01-22       Impact factor: 24.094

3.  In-Stent Restenosis: Pathophysiology and Treatment.

Authors:  Patrick M Looser; Luke K Kim; Dmitriy N Feldman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-02

4.  Clinical Outcomes of Drug-Eluting versus Bare-Metal In-Stent Restenosis after the Treatment of Drug-Eluting Stent or Drug-Eluting Balloon: A Systematic Review and Meta-Analysis.

Authors:  Yi-Xing Yang; Yin Liu; Chang-Ping Li; Peng-Ju Lu; Jiao Wang; Jing Gao
Journal:  J Interv Cardiol       Date:  2020-06-26       Impact factor: 2.279

5.  Bioresorbable vascular scaffold for coronary in-stent restenosis: a novel concept.

Authors:  Surender Deora; Sanjay Shah; Samir Pancholy; Tejas Patel
Journal:  Indian Heart J       Date:  2014-06-10

6.  First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients.

Authors:  Eliano Pio Navarese; Mariusz Kowalewski; David Kandzari; Alexandra Lansky; Bartosz Górny; Lukasz Kołtowski; Ron Waksman; Sergio Berti; Giuseppe Musumeci; Ugo Limbruno; Rene J van der Schaaf; Malte Kelm; Jacek Kubica; Harry Suryapranata
Journal:  Open Heart       Date:  2014-08-21

7.  Coronary stent thrombosis: current insights into new drug-eluting stent designs.

Authors:  Hyun Kuk Kim; Myung Ho Jeong
Journal:  Chonnam Med J       Date:  2012-12-21

8.  A rare and serious unforeseen complication of cutting balloon angioplasty.

Authors:  Praveen Vemula; Jagadeesh K Kalavakunta; George S Abela; Milind Karve
Journal:  Case Rep Cardiol       Date:  2014-03-23

9.  Comparative assessment of the antirestenotic efficacy of two paclitaxel drug-eluting balloons with different coatings in the treatment of in-stent restenosis.

Authors:  Freek Nijhoff; Pieter R Stella; Maartje S Troost; Anouar Belkacemi; Hendrik M Nathoe; Michiel Voskuil; Mariam Samim; Pieter A Doevendans; Pierfrancesco Agostoni
Journal:  Clin Res Cardiol       Date:  2015-11-05       Impact factor: 5.460

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.